Market Context — Why This Technology, Why Now

The pharmaceutical industry faces intense pressure to accelerate drug discovery while simultaneously reducing R&D costs and improving success rates. This technology directly addresses these challenges by offering a robust platform for high-throughput, high-fidelity drug screening. As personalized medicine and complex biologics gain traction, the ability to precisely model and analyze drug-membrane interactions becomes paramount, making this innovation timely for global adoption.

Key Competitive Advantages
01

Reduces New Drug Development Cycle by up to 50%

02

Reduces R&D Costs by ~$800K Annually (AI est.)

03

Mitigates Development Risk with High-Reliability Data

Market Opportunity
Pharmaceutical R&D Departments
$5B–$6B globally (AI est.)
Accelerating and enhancing the precision of screening in new drug development is a top priority, directly impacting cost reduction and time-to-market. This technology directly addresses these core needs.
Global pharmaceutical companies Contract research organizations (CROs) specializing in drug discovery Biotech firms focused on membrane protein therapeutics
Biotech Ventures and CROs
$300M–$400M in Japan (AI est.)
These entities actively invest in R&D and are keen to adopt innovative technologies. Efficiency improvements, especially in early-stage screening, are crucial for their business growth.
Emerging biotech startups Specialized contract research organizations (CROs) Diagnostic kit developers
Universities and Research Institutions
$600M–$700M in Japan (AI est.)
There is active research from basic to applied science using lipid bilayers for membrane protein studies and cell model research, driving high demand for precise experimental environments.
Academic research labs focusing on membrane biology Government-funded research institutes Core facilities offering advanced screening services
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

The patent protects an information processing device, control program, control method, control system, and drug screening method related to lipid bilayer control. Its successful registration after addressing a rejection, supported by a strong legal team, indicates robust and stable claims that are difficult to invalidate.

Competitive White Space

Adjacent areas for further IP development could include novel sensor integration methods for multi-modal observation, AI-driven predictive modeling for drug-membrane interactions, or advanced microfluidic designs for high-throughput multi-membrane arrays.

Economic Impact
~$800K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

A pharmaceutical R&D department employing 5 researchers for lipid bilayer screening, with an annual labor cost of ~$65K (AI est.) per researcher (total ~$350K (AI est.)), could see labor cost reductions of 20% (or ~$65K (AI est.)) due to improved experimental efficiency. Furthermore, shortened experimental periods and optimized reagent use are estimated to reduce annual reagent and equipment operating costs by approximately ~$450K (AI est.). This totals an expected R&D cost reduction of ~$800K (AI est.) per year per facility.

Speed to Market
4× faster than in-house development
This technology's lipid bilayer physical property control algorithm is established, with detailed configurations of observation and control mechanisms described in the patent specification. This allows adopting companies to significantly reduce the time required for integration into existing microfluidic devices and pipetting systems, as well as software development, compared to starting R&D from scratch. With the basic technical design complete, rapid transition to the validation and optimization phases for practical application is possible.
Competitive Positioning

X: Drug Screening Efficiency
Y: Experimental Data Reliability

Business Models & Applications
🤝 Technology Licensing
By obtaining a license for this technology, companies can integrate it into their products or services, launching new ventures or strengthening existing ones. This offers a competitive advantage, especially in the pharmaceutical and biotech sectors.
🔬 Joint Research and Development
Collaborative development of screening platforms tailored to specific drug targets or disease models, based on this technology, could lead to faster commercialization and market entry. Leveraging academic expertise through university partnerships is also possible.
⚙️ Device and System Sales
Developing and selling lipid bilayer control devices or integrated systems equipped with this technology to pharmaceutical companies and research institutions. Its high-precision control capabilities allow it to be positioned as a high-value-added product in the market.
Adjacent Application Opportunities
🧪 材料科学
High-Performance Membrane Development and Evaluation
This precision control technology for lipid bilayers could be applied to evaluate and develop high-performance materials such as separation membranes and sensor membranes. By stably altering membrane properties, it could accelerate the creation of novel functional materials, potentially reducing development cycles by 20-30%.
🧬 バイオセンサー
High-Sensitivity Biosensor Development
In biosensors utilizing lipid bilayers as sensing elements, precisely controlling membrane stability and responsiveness could lead to the development of new sensors with dramatically improved detection sensitivity and selectivity. This has potential applications in medical diagnostics and environmental monitoring, offering a 2-5x increase in detection accuracy.
🍔 食品・化粧品開発
Ingredient Permeation Mechanism Analysis
This technology's high-precision lipid bilayer model could enable detailed analysis of how active ingredients in food and cosmetics permeate cell membranes. This could support R&D aimed at improving product absorption efficiency and reducing side effects, potentially optimizing ingredient delivery by up to 30%.
Integration Roadmap — Estimated 12-Month Deployment
Requirements Definition and Basic Design
Duration: 3 months
Define detailed requirements for interfacing with the licensee's existing research equipment and target screening performance. Develop the basic design for the control module based on the patented technology.
Prototype Development and Validation
Duration: 6 months
Develop a prototype for the control program and its integration with observation and pipetting systems based on the basic design. Conduct validation of lipid bilayer physical quantity control stability and precision under actual experimental conditions.
System Integration and Optimization
Duration: 3 months
Optimize the system based on validation results and proceed with integration into the licensee's existing screening platform. Conduct final performance evaluations and create operational manuals for transition to full production.
Technical Feasibility
This technology is configured as an information processing device with observation and control means, allowing integration through software updates or module additions to existing microfluidic devices and pipetting systems. The claims describe specific mechanisms for observing physical quantities and performing feedback control, indicating high technical feasibility for adoption without significant capital investment by utilizing general-purpose sensors and precision pipettes.
Success Scenario
Upon adopting this technology, lipid bilayer stability in drug screening could dramatically improve, potentially increasing experimental reproducibility from the current 60% to 90%. This could significantly shorten the candidate substance evaluation cycle, estimated to increase the number of screenings possible per year by 1.5 times. As a result, it is expected to reduce drug development lead times and strengthen market competitiveness.
Patent Record
APPLICATION NO.
特願2021-014217
REGISTRATION NO.
7531903
FILING DATE
2021/02/01
GRANT DATE
2024/08/02
EXPIRATION DATE
2041/02/01
PATENT HOLDER
国立大学法人福井大学
Examination History
2023年11月22日
出願審査請求書
2024年05月07日
拒絶理由通知書
2024年06月25日
意見書
2024年06月25日
手続補正書（自発・内容）
2024年07月23日
特許査定